- Home
- VHUB vs MREO Comparison
VHUB vs MREO Comparison
Compare VHUB & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VHUB | MREO |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.0M | 52.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | VHUB | MREO |
|---|---|---|
| Price | $1.47 | $0.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 676.7K | ★ 1.8M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.20 |
| 52 Week High | $15.34 | $2.94 |
Technical Indicators
Market Signals| Indicator | VHUB | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 71.21 | 49.24 |
| Support Level | $0.58 | $0.21 |
| Resistance Level | N/A | $0.36 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 93.49 | 55.27 |
Price Performance
Historical ComparisonAbout VHUB VenHub Global Inc. Common Stock
Venhub Global Inc is engaged in designing and building autonomous Smart Stores that operate 24/7 without on-site staff. Each store combines robotic automation, real-time inventory tracking, and mobile-based checkout to provide secure, convenient retail access, and is offered as an integrated retail solution to store operators.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).